X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (52) 52
index medicus (51) 51
child (42) 42
child, preschool (39) 39
female (39) 39
male (39) 39
adolescent (37) 37
infant (33) 33
hematology (30) 30
children (29) 29
oncology (24) 24
treatment outcome (22) 22
pediatrics (19) 19
transplantation (19) 19
stem cells (15) 15
abridged index medicus (14) 14
adult (14) 14
antineoplastic combined chemotherapy protocols - therapeutic use (13) 13
bone-marrow-transplantation (13) 13
disease-free survival (13) 13
stem cell transplantation (13) 13
risk factors (12) 12
chemotherapy (11) 11
transplantation, homologous (11) 11
infant, newborn (10) 10
survival rate (10) 10
prognosis (9) 9
recurrence (9) 9
combined modality therapy (8) 8
hematopoietic stem cell transplantation (8) 8
hematopoietic stem cell transplantation - adverse effects (8) 8
leukemia (8) 8
follow-up studies (7) 7
immunology (7) 7
remission induction (7) 7
young adult (7) 7
antineoplastic combined chemotherapy protocols - adverse effects (6) 6
childhood (6) 6
hematopoietic stem cell transplantation - methods (6) 6
middle aged (6) 6
minimal residual disease (6) 6
neuroblastoma (6) 6
neuroblastoma - therapy (6) 6
prospective studies (6) 6
allogeneic transplantation (5) 5
hematopoietic stem cells (5) 5
proportional hazards models (5) 5
survival analysis (5) 5
therapy (5) 5
versus-host-disease (5) 5
adolescents (4) 4
bone marrow (4) 4
bone-marrow transplantation (4) 4
etoposide - administration & dosage (4) 4
health aspects (4) 4
hematology, oncology and palliative medicine (4) 4
hematopoietic stem cell transplantation - mortality (4) 4
mortality (4) 4
neoplasm recurrence, local - pathology (4) 4
patients (4) 4
pediatric-patients (4) 4
relapse (4) 4
retrospective studies (4) 4
survival (4) 4
transplantation chimera (4) 4
transplantation conditioning - methods (4) 4
acute lymphoblastic-leukemia (3) 3
acute myeloid-leukemia (3) 3
adolescence (3) 3
age (3) 3
bone marrow - pathology (3) 3
bone marrow transplantation (3) 3
bone-marrow (3) 3
cancer (3) 3
care and treatment (3) 3
chronic myelogenous leukemia (3) 3
chronic myeloid-leukemia (3) 3
classification (3) 3
cohort studies (3) 3
colony-stimulating factor (3) 3
diagnosis (3) 3
disease progression (3) 3
drug administration schedule (3) 3
gene (3) 3
germany - epidemiology (3) 3
graft vs host disease - etiology (3) 3
haplotypes (3) 3
hematopoietic chimerism (3) 3
histocompatibility testing (3) 3
immunophenotyping (3) 3
immunotherapy (3) 3
kaplan-meier estimate (3) 3
leukemia, myeloid, acute - mortality (3) 3
neoplasm recurrence, local - therapy (3) 3
neoplasm staging (3) 3
neuroblastoma - mortality (3) 3
precursor cell lymphoblastic leukemia-lymphoma - pathology (3) 3
precursor cell lymphoblastic leukemia-lymphoma - therapy (3) 3
predictive value of tests (3) 3
randomized-trial (3) 3
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


2012, ISBN 364216482X, Volume 5, 3
Reference
Journal Article
Journal Article
Journal Article
Leukemia, ISSN 0887-6924, 07/2018, Volume 32, Issue 7, pp. 1657 - 1669
A total of 156 patients (age range 1.3-18.0 years, median 13.2 years; 91 (58.3%) male) with newly diagnosed CML (N = 146 chronic phase (CML-CP), N = 3... 
CHRONIC MYELOGENOUS LEUKEMIA | TYROSINE KINASE INHIBITORS | RANDOMIZED CML | ONCOLOGY | COMPLETE MOLECULAR REMISSION | LONG-TERM SURVIVAL | MANAGING CHILDREN | RECEIVING IMATINIB | DOSE IMATINIB | STEM-CELL TRANSPLANTATION | HEMATOLOGY | EUROPEAN-LEUKEMIANET | Prognosis | Humans | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy | Child, Preschool | Infant | Male | Antineoplastic Agents - therapeutic use | Antineoplastic Agents - administration & dosage | Protein Kinase Inhibitors - adverse effects | Imatinib Mesylate - therapeutic use | Neoplasm Grading | Antineoplastic Agents - adverse effects | Imatinib Mesylate - adverse effects | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - pathology | Treatment Failure | Imatinib Mesylate - administration & dosage | Female | Child | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - mortality | Treatment Outcome | Combined Modality Therapy | Disease Progression | Protein Kinase Inhibitors - administration & dosage | Protein Kinase Inhibitors - therapeutic use | Bone Marrow - pathology | Adolescent | Biomarkers | Neoplasm Staging | Adolescence | Imatinib | Myeloid leukemia | Complications | Leukemia | Stem cell transplantation | Transplantation | Chronic myeloid leukemia | Survival | Patients | Molecular chains | Intolerance | Side effects | Failure analysis | Stem cells | Children | Adolescents | Index Medicus
Journal Article
JOURNAL OF ADOLESCENT AND YOUNG ADULT ONCOLOGY, ISSN 2156-5333, 06/2019, Volume 8, Issue 3, pp. 354 - 362
Purpose: We aimed to pilot and evaluate communication skills training (CST) for health care professionals (HCPs) interacting with adolescent patients with... 
YOUNG-ADULTS | BAD-NEWS | RESIDENTS | skills training | communication challenges | QUALITY | ONCOLOGY | FEASIBILITY | EFFICACY | CONSENSUS | CARE
Journal Article
Journal Article
Journal Article
Journal Article
Blood, ISSN 0006-4971, 07/2013, Volume 122, Issue 1, pp. 37 - 43
Journal Article